Drug Profile
Research programme: anti-cancer mRNA immunotherapies - BioNTech/Sanofi
Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator BioNTech
- Developer BioNTech; Sanofi
- Class Immunotherapies; RNA
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer